Johnson & Johnson (NYSE:JNJ) Stock Holdings Trimmed by Moody National Bank Trust Division

Moody National Bank Trust Division lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,911 shares of the company’s stock after selling 1,152 shares during the quarter. Johnson & Johnson comprises approximately 0.6% of Moody National Bank Trust Division’s investment portfolio, making the stock its 29th biggest holding. Moody National Bank Trust Division’s holdings in Johnson & Johnson were worth $5,338,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Talbot Financial LLC boosted its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Talbot Financial LLC now owns 101,236 shares of the company’s stock worth $14,641,000 after purchasing an additional 2,733 shares in the last quarter. Salem Investment Counselors Inc. increased its position in shares of Johnson & Johnson by 0.3% in the 4th quarter. Salem Investment Counselors Inc. now owns 179,539 shares of the company’s stock valued at $25,965,000 after buying an additional 503 shares in the last quarter. QV Investors Inc. lifted its stake in Johnson & Johnson by 7.8% in the 4th quarter. QV Investors Inc. now owns 104,940 shares of the company’s stock valued at $15,176,000 after acquiring an additional 7,570 shares in the last quarter. Agate Pass Investment Management LLC grew its stake in Johnson & Johnson by 10.2% in the fourth quarter. Agate Pass Investment Management LLC now owns 23,843 shares of the company’s stock valued at $3,448,000 after purchasing an additional 2,203 shares in the last quarter. Finally, Asset Allocation & Management Company LLC bought a new position in Johnson & Johnson during the 4th quarter worth $387,000. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $2.41 during trading hours on Monday, hitting $144.47. 5,477,616 shares of the company were exchanged, compared to its average volume of 7,666,393. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market capitalization of $347.83 billion, a price-to-earnings ratio of 20.91, a P/E/G ratio of 2.52 and a beta of 0.51. The business has a 50-day moving average of $149.67 and a 200-day moving average of $156.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm posted $2.66 earnings per share. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.43%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Bank of America reissued a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.